Avastin is one of Roche’s “big three” biologic drugs and generated sales of almost $6.8 billion in 2016 – around the same level as breast cancer drug Herceptin, while MabThera/Rituxan for ...

Amgen and Allergan's biosimilar of Roche’s cancer drug Avastin is on the cusp of approval in Europe, but a launch could be years away because of patent protection. While the US patent on Avastin ...

marketed as Tecentriq and Avastin by Roche (OTCQX:RHHBY) (OTCQX:RHHBF). The global Phase 1b/2 study tested amezalpat in combination with atezolizumab and bevacizumab against the standard of care ...

Recent studies highlight breakthroughs in medical treatments. A novel monoclonal antibody cocktail has shown promise in significantly extending progression-free survival for liver cancer patients.

But adding the combination of Astra Zeneca's Imfinzi, or durvalumab, and Roche's Avastin, or bevacizumab, to treatment with TACE improved median progression-free survival to 15 months, compared to ...

HK inno.N will handle domestic marketing and sales of the targeted cancer drug "Avastin" from global pharmaceutical company Roche for colorectal and gynecological cancers. HK inno.N noted on the ...